| pubmed-article:3987701 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3987701 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3987701 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3987701 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:3987701 | lifeskim:mentions | umls-concept:C1337013 | lld:lifeskim |
| pubmed-article:3987701 | lifeskim:mentions | umls-concept:C0040123 | lld:lifeskim |
| pubmed-article:3987701 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:3987701 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:3987701 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:3987701 | pubmed:issue | 5-6 | lld:pubmed |
| pubmed-article:3987701 | pubmed:dateCreated | 1985-6-10 | lld:pubmed |
| pubmed-article:3987701 | pubmed:abstractText | Serum thyroglobulin (Tg) was measured in 429 patients with well-differentiated thyroid carcinoma, during thyroid hormone suppression therapy. 324 patients out of 429 were considered free of disease; 44 had only remnants in the thyroid bed; 61 had metastases, of them 40 were detected by TBS and 21 were nonfunctioning and were detected by other diagnostic procedures. Tg was measured by a RIA method in 257 patients and by an IRMA method in 277 patients. The correlation between the two methods was very good (r = 0.914) for values higher than 25 ng/ml with the RIA method. The cut-off limit to distinguish pathological from nonpathological values was considered the mean value found in the patients free of disease plus 2SD. The cut-off limit for the RIA method was 24.2 ng/ml and 3.0 ng/ml for the IRMA method. Of patients with high Tg levels 92% had metastases, either nodal or distant; only 8% had remnants in the thyroid bed. Tg levels were high in 80% of the patients with metastases, all but two of the patients with metastases and low Tg levels had nodal metastases. Moreover, Tg levels were high in 76% of the patients with metastases unable to take up radioiodine. In conclusion: patients with low levels of serum Tg during suppression therapy have a high probability of being free of disease, even though the presence of tumors cannot be excluded. On the other hand a value greater than the cut-off limit suggests the presence of metastases despite a negative scan. | lld:pubmed |
| pubmed-article:3987701 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3987701 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3987701 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3987701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3987701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3987701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3987701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3987701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3987701 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3987701 | pubmed:issn | 0340-6997 | lld:pubmed |
| pubmed-article:3987701 | pubmed:author | pubmed-author:BetterleCC | lld:pubmed |
| pubmed-article:3987701 | pubmed:author | pubmed-author:CasaraDD | lld:pubmed |
| pubmed-article:3987701 | pubmed:author | pubmed-author:PiccoliGG | lld:pubmed |
| pubmed-article:3987701 | pubmed:author | pubmed-author:BusnardoBB | lld:pubmed |
| pubmed-article:3987701 | pubmed:author | pubmed-author:GirelliM EME | lld:pubmed |
| pubmed-article:3987701 | pubmed:author | pubmed-author:PelizzoM RMR | lld:pubmed |
| pubmed-article:3987701 | pubmed:author | pubmed-author:AmerioRR | lld:pubmed |
| pubmed-article:3987701 | pubmed:author | pubmed-author:ScottonGG | lld:pubmed |
| pubmed-article:3987701 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3987701 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:3987701 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3987701 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3987701 | pubmed:pagination | 252-4 | lld:pubmed |
| pubmed-article:3987701 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:meshHeading | pubmed-meshheading:3987701-... | lld:pubmed |
| pubmed-article:3987701 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3987701 | pubmed:articleTitle | Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy: study on 429 patients. | lld:pubmed |
| pubmed-article:3987701 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3987701 | lld:pubmed |
